Genmab Shares Outstanding 2019-2022 | GMAB

Genmab shares outstanding history from 2019 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Genmab shares outstanding for the quarter ending September 30, 2022 were 0.659B, a 0.24% decline year-over-year.
  • Genmab 2021 shares outstanding were 0.66B, a 0.24% increase from 2020.
  • Genmab 2020 shares outstanding were 0.659B, a 3.53% increase from 2019.
  • Genmab 2019 shares outstanding were 0.636B, a 2.58% increase from 2018.
Genmab Annual Shares Outstanding
(Millions of Shares)
2021 660
2020 659
2019 636
2018 620
Genmab Quarterly Shares Outstanding
(Millions of Shares)
2022-09-30 659
2022-06-30 660
2022-03-31 660
2021-12-31 660
2021-09-30 661
2021-06-30 660
2021-03-31 660
2020-12-31 659
2020-09-30 659
2020-06-30 658
2020-03-31 658
2019-12-31 636
2019-09-30 649
2019-06-30 629
2019-03-31 62
2018-12-31 62
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $25.237B $1.349B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00